Skip to main content
. 2010 Jul 1;2:75–85. doi: 10.2147/ceor.s10835

Figure 1B.

Figure 1B

Cost-effectiveness plane for patients receiving a first prescription of ICS (revised asthma control).

Note: Asthma control (revised) was defined as asthma control plus average daily short-acting β2 agonist use restricted to ≤200 μg salbutamol and ≤500 μg terbutaline.